New Enterprise Associates 15, L.P.
CIK 0001629794 Name as filed on the most recent filing
Filed as New Enterprise Associates 15, L.P. (26)
40 transaction lines · from 26 filings · filed 2016-12-19 to 2025-10-06 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER NeueHealth, Inc. 1 filings
- ISSUER Arcellx, Inc. 2 filings
- ISSUER IonQ, Inc. 1 filings
- ISSUER Reneo Pharmaceuticals, Inc. 1 filings
- ISSUER Eargo, Inc. 1 filings
- ISSUER Inozyme Pharma, Inc. 1 filings
- ISSUER Nkarta, Inc. 1 filings
- ISSUER Aveo Pharmaceuticals, Inc. 16 filings
- ISSUER Arca biopharma, Inc. 1 filings
- ISSUER Achaogen Inc 1 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2025-10-02 |
NeueHealth, Inc. NEUE |
S, Open-market sale | 280 disposed | 6.75 | 1,890.00 | Form 4, filing 0001193125-25-232128 | |
| 2022-06-21 |
Arcellx, Inc. ACLX |
P, Open-market purchase | 312,500 acquired | 16.00 | 5,000,000.00 | Form 4, filing 0001209191-22-038994 | |
| 2022-05-31 |
IonQ, Inc. IONQ |
S, Open-market sale | 498,614 disposed | 5.65 | 2,815,374.09 | Form 4, filing 0001209191-22-032835 | |
| 2022-05-27 |
IonQ, Inc. IONQ |
S, Open-market sale | 1,497,733 disposed | 5.93 | 8,880,358.50 | Form 4, filing 0001209191-22-032835 | |
| 2022-05-26 |
IonQ, Inc. IONQ |
S, Open-market sale | 926,619 disposed | 5.80 | 5,377,726.03 | Form 4, filing 0001209191-22-032835 | |
| 2022-02-08 |
Arcellx, Inc. ACLX |
P, Open-market purchase | 1,583,333 acquired | 15.00 | 23,749,995.00 | Form 4, filing 0001209191-22-008192 | |
| 2021-04-13 |
Reneo Pharmaceuticals, Inc. RPHM |
P, Open-market purchase | 666,666 acquired | 15.00 | 9,999,990.00 | Form 4, filing 0001209191-21-026862 | |
| 2020-10-20 |
Eargo, Inc. EAR |
P, Open-market purchase | 311,111 acquired | 18.00 | 5,599,998.00 | Form 4, filing 0001209191-20-055616 | |
| 2020-07-28 |
Inozyme Pharma, Inc. INZY |
P, Open-market purchase | 250,000 acquired | 16.00 | 4,000,000.00 | Form 4, filing 0001209191-20-043880 | |
| 2020-07-14 |
Nkarta, Inc. NKTK |
P, Open-market purchase | 666,666 acquired | 18.00 | 11,999,988.00 | Form 4, filing 0001209191-20-042657 | |
| 2020-06-19 |
Aveo Pharmaceuticals, Inc. AVEO |
P, Open-market purchase | 1,428,571 acquired | 5.25 | 7,499,997.75 | Form 4, filing 0001209191-20-038234 | |
| 2019-04-08 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 4,347,827 acquired | 1.14 | 4,956,522.78 | Form 4, filing 0001209191-19-023995 | |
| 2018-12-21 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 300,000 acquired | 1.49 | 448,380.00 | Form 4, filing 0001209191-18-064024 | |
| 2018-12-20 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 200,000 acquired | 1.63 | 326,060.00 | Form 4, filing 0001209191-18-064024 | |
| 2018-12-11 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 61,200 acquired | 1.98 | 121,084.20 | Form 4, filing 0001209191-18-062247 | |
| 2018-12-10 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 26,000 acquired | 1.98 | 51,576.20 | Form 4, filing 0001209191-18-061832 | |
| 2018-12-07 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 117,100 acquired | 1.98 | 232,361.53 | Form 4, filing 0001209191-18-061832 | |
| 2018-12-06 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 27,300 acquired | 1.99 | 54,414.36 | Form 4, filing 0001209191-18-061832 | |
| 2018-11-30 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 71,900 acquired | 1.98 | 142,067.21 | Form 4, filing 0001209191-18-060414 | |
| 2018-11-28 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 24,500 acquired | 1.99 | 48,823.60 | Form 4, filing 0001209191-18-060414 | |
| 2018-11-20 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 170,000 acquired | 1.98 | 336,107.00 | Form 4, filing 0001209191-18-059729 | |
| 2018-11-19 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 510,000 acquired | 1.88 | 956,658.00 | Form 4, filing 0001209191-18-059344 | |
| 2018-11-16 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 350,000 acquired | 1.86 | 649,355.00 | Form 4, filing 0001209191-18-059344 | |
| 2018-11-15 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 340,000 acquired | 1.86 | 631,958.00 | Form 4, filing 0001209191-18-059344 | |
| 2018-08-21 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 663,716 acquired | 2.26 | 1,499,998.16 | Form 4, filing 0001209191-18-047958 | |
| 2018-07-19 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 50,600 acquired | 2.00 | 101,164.58 | Form 4, filing 0001209191-18-043476 | |
| 2018-07-18 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 200,000 acquired | 1.95 | 390,580.00 | Form 4, filing 0001209191-18-043476 | |
| 2018-06-28 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 187,130 acquired | 2.10 | 392,692.30 | Form 4, filing 0001209191-18-039956 | |
| 2018-06-27 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 5,295 acquired | 2.15 | 11,384.25 | Form 4, filing 0001209191-18-039956 | |
| 2018-05-30 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 275 acquired | 2.15 | 591.25 | Form 4, filing 0001209191-18-034183 | |
| 2018-05-21 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 32,200 acquired | 2.14 | 69,059.34 | Form 4, filing 0001209191-18-031981 | |
| 2018-05-18 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 20,100 acquired | 2.14 | 42,927.57 | Form 4, filing 0001209191-18-031981 | |
| 2018-05-17 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 184,179 acquired | 2.13 | 391,435.63 | Form 4, filing 0001209191-18-031981 | |
| 2018-05-08 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 70,873 acquired | 2.13 | 151,250.07 | Form 4, filing 0001209191-18-029293 | |
| 2018-04-10 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 203,200 acquired | 2.46 | 499,993.92 | Form 4, filing 0001209191-18-024532 | |
| 2018-04-09 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 32,100 acquired | 2.43 | 78,099.30 | Form 4, filing 0001209191-18-024532 | |
| 2018-04-06 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 685,676 acquired | 2.24 | 1,536,942.75 | Form 4, filing 0001209191-18-024532 | |
| 2018-02-26 |
Arca biopharma, Inc. ABIO |
S, Open-market sale | 1,460,209 disposed | 0.50 | 731,272.67 | Form 4, filing 0001209191-18-013927 | |
| 2017-03-28 |
Aveo Pharmaceuticals Inc AVEO |
P, Open-market purchase | 6,000,000 acquired | 0.50 | 3,000,000.00 | Form 4, filing 0001209191-17-023485 | |
| 2016-12-19 |
Achaogen Inc AKAO |
P, Open-market purchase | 500,000 acquired | 13.50 | 6,750,000.00 | Form 4, filing 0001209191-16-155933 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. New Enterprise Associates 15, L.P., insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001629794
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6